DK3110434T3 - Uti fusionsproteiner - Google Patents
Uti fusionsproteiner Download PDFInfo
- Publication number
- DK3110434T3 DK3110434T3 DK15708411.2T DK15708411T DK3110434T3 DK 3110434 T3 DK3110434 T3 DK 3110434T3 DK 15708411 T DK15708411 T DK 15708411T DK 3110434 T3 DK3110434 T3 DK 3110434T3
- Authority
- DK
- Denmark
- Prior art keywords
- gly
- ser
- val
- glu
- lys
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
- C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
Claims (10)
1. UTI-fusionsprotein omfattende SEQ ID NO:1.
2. Isoleret UTI-fusionsprotein omfattende SEQ ID NO:1.
3. UTI-fusionsprotein ifølge et hvilket som helst af kravene 1 og 2, hvor fusionsproteinet er en dimer og omfatter Fc-domæner der er associeret kovalent.
4. Farmaceutisk sammensætning omfattende UTI-fusionsprotein ifølge et hvilket som helst af kravene 1, 2 og 3 og en farmaceutisk acceptabel excipiens.
5. UTI-fusionsprotein ifølge et hvilket som helst af kravene 1, 2 og 3 til anvendelse som et medikament.
6. UTI-fusionsprotein ifølge et hvilket som helst af kravene 1, 2 og 3 til anvendelse i behandling af pankreatitis, herunder endoskopi-induceret pancreatitis og akut pancreatitis; arthritis, SARS, systemisk inflammatorisk responssyndrom, akut kredsløbsfejl, sepsis, hepatitis, appendicitis, colitis, organsvigt, organskade, herunder skade på bugspytkirtel, nyre eller lunge; reperfusionsskade, Stevens-Johnson-syndrom, toxisk epidermal nekrolyse, shock, iskæmiske skader, akut lungeskade, herunder lungeskade forårsaget af akut aortadissektion; astma, lungebetændelse, pneumoni, herunder ventilatorassocieret pneumoni; dissemineret intravaskulær koagulation eller akut respiratorisk distress syndrom.
7. Nukleinsyre omfattende en polynukleotidsekvens der koder for SEQ ID NO:1.
8. Ekspressionsvektor omfattende en nukleinsyre ifølge krav 7.
9. Rekombinant værtscelle omfattende en ekspressionsvektor ifølge krav 8.
10. Fremgangsmåde til fremstilling af et UTI-fusionsprotein, omfattende: anbringelse afen rekombinant værtscelle ifølge krav 9 i et vækstmedium, således at et rekombinant fusionsprotein udtrykkes, og isolere det rekombinante fusionsprotein fra cellen eller vækstmediet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461943617P | 2014-02-24 | 2014-02-24 | |
| PCT/US2015/017152 WO2015127391A1 (en) | 2014-02-24 | 2015-02-23 | Uti fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3110434T3 true DK3110434T3 (da) | 2019-01-14 |
Family
ID=52629709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15708411.2T DK3110434T3 (da) | 2014-02-24 | 2015-02-23 | Uti fusionsproteiner |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US9856310B2 (da) |
| EP (2) | EP3110434B1 (da) |
| JP (4) | JP6574431B2 (da) |
| KR (2) | KR20220151005A (da) |
| CN (2) | CN110092837B (da) |
| AR (1) | AR101597A1 (da) |
| AU (4) | AU2015218704B2 (da) |
| BR (1) | BR112016019390B1 (da) |
| CA (2) | CA3178241A1 (da) |
| CL (1) | CL2016002136A1 (da) |
| CR (1) | CR20160444A (da) |
| CY (1) | CY1120997T1 (da) |
| DK (1) | DK3110434T3 (da) |
| DO (1) | DOP2016000202A (da) |
| EA (2) | EA037256B1 (da) |
| EC (1) | ECSP16076535A (da) |
| ES (1) | ES2700149T3 (da) |
| GE (1) | GEP20196970B (da) |
| HR (1) | HRP20182029T1 (da) |
| IL (1) | IL247321B (da) |
| JO (1) | JO3729B1 (da) |
| LT (1) | LT3110434T (da) |
| MA (1) | MA39347B2 (da) |
| MX (2) | MX2016010950A (da) |
| MY (1) | MY178774A (da) |
| NZ (3) | NZ760008A (da) |
| PE (1) | PE20170257A1 (da) |
| PH (1) | PH12016501629A1 (da) |
| PL (1) | PL3110434T3 (da) |
| PT (1) | PT3110434T (da) |
| RS (1) | RS58285B1 (da) |
| SG (2) | SG10201708400QA (da) |
| SI (1) | SI3110434T1 (da) |
| TW (1) | TWI694084B (da) |
| UA (1) | UA118866C2 (da) |
| WO (1) | WO2015127391A1 (da) |
| ZA (1) | ZA201606327B (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110092837B (zh) * | 2014-02-24 | 2024-01-02 | 武田有限公司 | Uti融合蛋白 |
| WO2018226887A1 (en) * | 2017-06-07 | 2018-12-13 | Spark Therapeutics, Inc. | ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION |
| WO2020106881A1 (en) * | 2018-11-20 | 2020-05-28 | Diamedica Inc. | Modified ulinastatin polypeptides |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| WO2021178843A1 (en) * | 2020-03-05 | 2021-09-10 | DiaMedica USA Inc. | Ulinastatin polypeptides |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663143A (en) * | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| EP0401508B1 (de) * | 1989-05-13 | 1994-11-23 | Bayer Ag | Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
| AU641568B2 (en) | 1990-11-13 | 1993-09-23 | Mochida Pharmaceutical Co., Ltd. | Polypeptide,DNA fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same |
| JP2769083B2 (ja) | 1993-02-22 | 1998-06-25 | 日清食品株式会社 | エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法 |
| PL188387B1 (pl) | 1996-03-11 | 2005-01-31 | Bayer Ag | Białko o aktywności hamującej proteazę serynową, kompozycja farmaceutyczna, wyodrębniona sekwencja,samopowtarzający się wektor, zastosowanie białka o aktywności proteazy serynowej, sposób hamowania aktywności proteazy serynowej ex vivo i sposób wytwarzania białka |
| DE19725014A1 (de) | 1997-06-13 | 1998-12-17 | Bayer Ag | Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten |
| KR100942849B1 (ko) * | 2004-03-30 | 2010-02-17 | 글락소 그룹 리미티드 | 면역글로불린 |
| US20080181892A1 (en) * | 2004-08-11 | 2008-07-31 | Trubion Pharmaceuticals | Binding Domain Fusion Protein |
| EP1889908A4 (en) * | 2005-06-03 | 2012-04-25 | Mochida Pharm Co Ltd | PROTEIN FUSED WITH ANTI-CD14 ANTIBODY |
| AU2006332774A1 (en) | 2005-12-29 | 2007-07-12 | Dyax Corp. | Protease inhibition |
| WO2010035012A1 (en) * | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| CN101721699B (zh) * | 2008-10-13 | 2012-11-07 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用 |
| CN102580085B (zh) * | 2008-10-13 | 2013-09-18 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗脓毒症药物中的应用 |
| WO2010129600A2 (en) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| CN103930127B (zh) * | 2011-04-29 | 2018-01-09 | 华盛顿大学 | 治疗性核酸酶组合物和方法 |
| US8619331B2 (en) | 2011-07-19 | 2013-12-31 | Xerox Corporation | Simulated paper texture using clear toner and glossmark on texture-less stock |
| EP2785744B1 (en) * | 2011-12-01 | 2017-10-04 | AP Biosciences, Inc. | Protein inhibitors to complement and vegf pathways and methods of use thereof |
| CA2871468C (en) * | 2012-04-23 | 2021-09-21 | Nrl Pharma, Inc. | Lactoferrin fusion protein and method for preparation thereof |
| CN103044554B (zh) * | 2012-05-14 | 2014-08-27 | 旭华（上海）生物研发中心有限公司 | 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用 |
| JP2013253079A (ja) * | 2012-05-14 | 2013-12-19 | Xuhua (Shanghai) Biological Research & Development Center Co Ltd | 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用 |
| CN110092837B (zh) * | 2014-02-24 | 2024-01-02 | 武田有限公司 | Uti融合蛋白 |
-
2015
- 2015-02-23 CN CN201910282497.3A patent/CN110092837B/zh active Active
- 2015-02-23 CR CR20160444A patent/CR20160444A/es unknown
- 2015-02-23 KR KR1020227037377A patent/KR20220151005A/ko not_active Application Discontinuation
- 2015-02-23 MX MX2016010950A patent/MX2016010950A/es active IP Right Grant
- 2015-02-23 UA UAA201609101A patent/UA118866C2/uk unknown
- 2015-02-23 JP JP2016553562A patent/JP6574431B2/ja active Active
- 2015-02-23 SG SG10201708400QA patent/SG10201708400QA/en unknown
- 2015-02-23 EA EA201691702A patent/EA037256B1/ru unknown
- 2015-02-23 AU AU2015218704A patent/AU2015218704B2/en active Active
- 2015-02-23 SI SI201530516T patent/SI3110434T1/sl unknown
- 2015-02-23 NZ NZ760008A patent/NZ760008A/en unknown
- 2015-02-23 SG SG11201606691QA patent/SG11201606691QA/en unknown
- 2015-02-23 KR KR1020167026429A patent/KR102461210B1/ko active IP Right Grant
- 2015-02-23 PL PL15708411T patent/PL3110434T3/pl unknown
- 2015-02-23 WO PCT/US2015/017152 patent/WO2015127391A1/en active Application Filing
- 2015-02-23 CA CA3178241A patent/CA3178241A1/en active Pending
- 2015-02-23 DK DK15708411.2T patent/DK3110434T3/da active
- 2015-02-23 NZ NZ760789A patent/NZ760789A/en unknown
- 2015-02-23 MA MA39347A patent/MA39347B2/fr unknown
- 2015-02-23 CN CN201580014645.3A patent/CN106232135B/zh active Active
- 2015-02-23 GE GEAP201514277A patent/GEP20196970B/en unknown
- 2015-02-23 NZ NZ724196A patent/NZ724196A/en unknown
- 2015-02-23 EP EP15708411.2A patent/EP3110434B1/en active Active
- 2015-02-23 PT PT15708411T patent/PT3110434T/pt unknown
- 2015-02-23 LT LTEP15708411.2T patent/LT3110434T/lt unknown
- 2015-02-23 RS RS20181514A patent/RS58285B1/sr unknown
- 2015-02-23 US US15/120,956 patent/US9856310B2/en active Active
- 2015-02-23 EP EP18192690.8A patent/EP3443978A1/en active Pending
- 2015-02-23 CA CA2939639A patent/CA2939639C/en active Active
- 2015-02-23 ES ES15708411T patent/ES2700149T3/es active Active
- 2015-02-23 MY MYPI2016703046A patent/MY178774A/en unknown
- 2015-02-23 PE PE2016001522A patent/PE20170257A1/es unknown
- 2015-02-23 EA EA202091567A patent/EA202091567A1/ru unknown
- 2015-02-23 BR BR112016019390-3A patent/BR112016019390B1/pt active IP Right Grant
- 2015-08-20 JO JOP/2015/0200A patent/JO3729B1/ar active
- 2015-08-20 AR ARP150102677A patent/AR101597A1/es unknown
- 2015-08-21 TW TW104127393A patent/TWI694084B/zh active
-
2016
- 2016-08-10 DO DO2016000202A patent/DOP2016000202A/es unknown
- 2016-08-16 PH PH12016501629A patent/PH12016501629A1/en unknown
- 2016-08-17 IL IL247321A patent/IL247321B/en active IP Right Grant
- 2016-08-23 MX MX2019013124A patent/MX2019013124A/es unknown
- 2016-08-24 CL CL2016002136A patent/CL2016002136A1/es unknown
- 2016-09-13 ZA ZA2016/06327A patent/ZA201606327B/en unknown
- 2016-09-23 EC ECIEPI201676535A patent/ECSP16076535A/es unknown
-
2017
- 2017-11-27 US US15/823,398 patent/US10351618B2/en active Active
-
2018
- 2018-12-03 HR HRP20182029TT patent/HRP20182029T1/hr unknown
- 2018-12-18 CY CY181101355T patent/CY1120997T1/el unknown
-
2019
- 2019-02-15 US US16/277,606 patent/US20200040062A1/en not_active Abandoned
- 2019-06-11 JP JP2019109054A patent/JP6938565B2/ja active Active
- 2019-06-25 AU AU2019204448A patent/AU2019204448B2/en active Active
-
2021
- 2021-06-03 US US17/337,922 patent/US20220127334A1/en active Pending
- 2021-08-31 AU AU2021225156A patent/AU2021225156B2/en active Active
- 2021-09-01 JP JP2021142544A patent/JP2022002513A/ja active Pending
-
2023
- 2023-02-16 AU AU2023200875A patent/AU2023200875A1/en active Pending
- 2023-06-30 JP JP2023108024A patent/JP2023123763A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3110434T3 (da) | Uti fusionsproteiner | |
| DK2814502T3 (da) | Von Willebrand Faktor varianter med forbedret Faktor VIII bindingsaffinitet | |
| KR20150041628A (ko) | 인터루킨-2 융합 단백질 및 그의 용도 | |
| JP2012525847A (ja) | Ｆｇｆ２１変異体およびその使用 | |
| TWI835773B (zh) | 組合物及使用方法 | |
| AU2015283822B2 (en) | Modified von willebrand factor | |
| KR20180098404A (ko) | 돌연변이된 폰 빌레브란트 인자 | |
| KR20240051971A (ko) | 액티빈 수용체 ii형 신호전달 억제제를 이용한 방법 | |
| JP2022512541A (ja) | Ｐｄ－１系キメラタンパク質を含む併用療法 | |
| JP2013253079A (ja) | 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用 | |
| BR122023015739B1 (pt) | Proteínas de fusão uti, seus usos,composição farmacêutica compreendendo a referida proteína e método de produção de uma proteína de fusão uti |